Very long-chain n-3 fatty acids and human health: Fact, fiction and the future

Proceedings of the Nutrition Society

Volumn 77, Issue 1, 2018, Pages 52-72

  Calder, P C ^a,b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Brain; Cancer; CVD; Development; DHA; Eicosanoids; EPA; Fish oil; Inflammation

Indexed keywords

CHOLESTEROL ESTER; DOCOSAPENTAENOIC ACID; FISH OIL; MEMBRANE PROTEIN; OMEGA 3 FATTY ACID; PHOSPHOLIPID; VERY LONG CHAIN FATTY ACID; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; UNSATURATED FATTY ACID;

ALZHEIMER DISEASE; ATTENTION DEFICIT DISORDER; BRAIN DEVELOPMENT; CELL MEMBRANE; CELL STRUCTURE; COGNITIVE DEFECT; CONDUCT DISORDER; CONFERENCE PAPER; DEPRESSION; ESTERIFICATION; EYE DEVELOPMENT; FAT INTAKE; FATTY ACID OXIDATION; FATTY ACID TRANSPORT; FISH; GENE EXPRESSION; HUMAN; IMMUNOMODULATION; LIPID COMPOSITION; LIPOGENESIS; MEMORY CONSOLIDATION; MENTAL DISEASE; NERVE DEGENERATION; NUTRITIONAL REQUIREMENT; DRUG EFFECT; EATING; LIPID METABOLISM; METABOLISM; PHARMACOLOGY; PHYSIOLOGY;

CELL MEMBRANE; DIETARY FATS; DOCOSAHEXAENOIC ACIDS; EATING; EICOSAPENTAENOIC ACID; FATTY ACIDS, UNSATURATED; GENE EXPRESSION; HUMANS; LIPID METABOLISM; MEMBRANE PROTEINS;

EID: 85031908256     PISSN: 00296651     EISSN: 14752719     Source Type: Journal    
DOI: 10.1017/S0029665117003950     Document Type: Conference Paper

References (275)

1. Burdge GC & Calder PC (2015) Introduction to fatty acids and lipids. World Rev Nutr Diet 112, 1-16.
2. Calder PC & Yaqoob P (2009) Understanding omega-3 polyunsaturated fatty acids. Postgrad Med 121, 148-157.
3. Calder PC (2014) Very long chain omega-3 (n-3) fatty acids and human health. Eur J Lipid Sci Technol 116, 1280-1300.
4. Kaur G, Cameron-Smith D, Garg M et al. (2011) Docosapentaenoic acid (22:5n-3): a review of its biological effects. Prog. Lipid Res 50, 28-34.
5. Weylandt KH (2016) Docosapentaenoic acid derived metabolites and mediators - the new world of lipid mediator medicine in a nutshell. Eur J Pharmacol 785, 108-115.
6. Blasbalg TL, Hibbeln JR, Ramsden CE et al. (2011) Changes in consumption of omega-3 and omega-6 fatty acids in the United States during the 20th century. Am J Clin Nutr 93, 950-962.
7. Arterburn LM, Hall EB & Oken H (2006) Distribution, interconversion, and dose response of n-3 fatty acids in humans. Am J Clin Nutr 83, 1467S-1476S.
8. Baker EJ, Miles EA, Burdge GC et al. (2016) Metabolism and functional effects of plant-derived omega-3 fatty acids in humans. Prog Lipid Res 64, 30-56.
9. Bolton-Smith C, Woodward M & Tavendale R (1997) Evidence for age-related differences in the fatty acid composition of human adipose tissue, independent of diet. Eur J Clin Nutr 51, 619-624.
10. Childs CE, Romeu-Nadal M, Burdge GC et al. (2008) Gender differences in the n-3 fatty acid content of tissues. Proc Nutr Soc 67, 19-27.
11. Burdge GC, Jones AE & Wootton SA (2002) Eicosapentaenoic and docosapentaenoic acids are the principal products of alpha-linolenic acid metabolism in young men. Brit J Nutr 88, 355-363.
12. Burdge GC & Wootton SA (2002) Conversion of alphalinolenic acid to eicosapentaenoic, docosapentaenoic and docosahexaenoic acids in young women. Brit J Nutr 88, 411-420.
13. Vessby B, Gustafsson IB, Tengblad S et al. (2002) Desaturation and elongation of fatty acids and insulin action. Ann NY Acad Sci 967, 183-195.
14. Koletzko B, Lattka E, Zeilinger S et al. (2011) Genetic variants of the fatty acid desaturase gene cluster predict amounts of red blood cell docosahexaenoic acid and other polyunsaturated fatty acids in pregnant women: findings from the Avon Longitudinal Study of Parents and Children. Am J Clin Nutr 93, 211-219.
15. British Nutrition Foundation (1999) N-3 Fatty Acids and Health. London: British Nutrition Foundation.
16. Calder PC (2017) Omega-3: the good oil. Nutr Bull 42, 132-140.
17. Scientific Advisory Committee on Nutrition/Committee on Toxicity (2004) Advice on Fish Consumption: Benefits and Risks. London: TSO.
18. Meyer BJ, Mann NJ, Lewis JL et al. (2003) Dietary intakes and food sources of omega-6 and omega-3 polyunsaturated fatty acids. Lipids 38, 391-398.
19. Howe P, Meyer B, Record S et al. (2006) Dietary intake of long-chain omega-3 polyunsaturated fatty acids: contribution of meat sources. Nutrition 22, 47-53.
20. Rahmawaty S, Charlton K, Lyons-Wall P et al. (2013) Dietary intake and food sources of EPA, DPA and DHA in Australian children. Lipids 48, 869-877.
21. Stubbs CD & Smith AD (1984) The modification of mammalian membrane polyunsaturated fatty acid composition in relation to membrane fluidity and function. Biochim Biophys Acta 779, 89-137.
22. Brenner RR (1984) Effect of unsaturated fatty acids on membrane structure and enzyme kinetics. Prog Lipid Res 23, 69-96.
23. Murphy MG (1990) Dietary fatty acids and membrane protein function. J Nutr Biochem 1, 68-79.
24. Browning LM, Walker CG, Mander AP et al. (2012) Incorporation of eicosapentaenoic and docosahexaenoic acids into lipid pools when given as supplements providing doses equivalent to typical intakes of oily fish. Am J Clin Nutr 96, 748-758.
25. Miles EA, Noakes PS, Kremmyda LS et al. (2011) The Salmon in Pregnancy Study: study design, subject characteristics, maternal fish and marine n-3 fatty acid intake, and marine n-3 fatty acid status in maternal and umbilical cord blood. Am J Clin Nutr 94, 1986S-1992S.
26. Healy DA, Wallace FA, Miles EA et al. (2000) The effect of low to moderate amounts of dietary fish oil on neutrophil lipid composition and function. Lipids 35, 763-768.
27. Skinner ER, Watt C, Besson JA et al. (1993) Differences in the fatty acid composition of the grey and white matter of different regions of the brains of patients with Alzheimer's disease and control subjects. Brain 116, 717-725.
28. Makrides M, Neumann MA, Byard RW et al. (1994) Fatty acid composition of brain, retina, and erythrocytes in breast- and formula-fed infants. Am J Clin Nutr 60, 189-194.
29. Harris WS, Sands SA, Windsor SL et al. (2004) Omega-3 fatty acids in cardiac biopsies from heart transplantation patients: correlation with erythrocyes and response to supplementation. Circulation 110, 1645-1649.
30. Metcalf RG, James MJ, Gibson RA et al. (2007) Effects of fish-oil supplementation on myocardial fatty acids in humans. Am J Clin Nutr 85, 1222-1228.
31. McGlory C, Galloway SD, Hamilton DL et al. (2014) Temporal changes in human skeletal muscle and blood lipid composition with fish oil supplementation. Prostagland Leukotr Essent Fatty Acids 90, 199-206.
32. Smith GI, Atherton P, Reeds DN et al. (2011) Omega-3 polyunsaturated fatty acids augment the muscle protein anabolic response to hyperinsulinaemia-hyperaminoacidaemia in healthy young and middle-aged men and women. Clin Sci 121, 267-278.
33. Araya J, Rodrigo R, Videla LA et al. (2004) Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci 106, 635-643.
34. Elizondo A, Araya J, Rodrigo R et al. (2007) Polyunsaturated fatty acid pattern in liver and erythrocyte phospholipids from obese patients. Obesity 15, 24-31.
35. Hillier K, Jewell R, Dorrell L et al. (1991) Incorporation of fatty acids from fish oil and olive oil into colonic mucosal lipids and effects upon eicosanoid synthesis in inflammatory bowel disease. Gut 32, 1151-1155.
36. Safarinejad MR (2011) Effect of omega-3 polyunsaturated fatty acid supplementation on semen profile and enzymatic anti-oxidant capacity of seminal plasma in infertile men with idiopathic oligoasthenoteratospermia: a doubleblind, placebo-controlled, randomised study. Andrologia 43, 38-47.
37. Crawford MA, Casperd NM & Sinclair AJ (1976) The long chain metabolites of linoleic and linolenic acids in liver and brain in herbivores and carnivores. Comp Biochem Physiol 54B, 395-401.
38. Anderson RE (1970) Lipids of ocular tissues. IV. A comparison of the phospholipids from the retina of six mammalian species. Exp Eye Res 10, 339-344.
39. von Schacky C, Fischer S & Weber PC (1985) Long term effects of dietary marine ω-3 fatty acids upon plasma and cellular lipids, platelet function, and eicosanoid formation in humans. J Clin Invest 76, 1626-1631.
40. Harris WS, Windsor SL & Dujovne CA (1991) Effects of four doses of n-3 fatty acids given to hyperlipidemic patients for six months. J Am Coll Nutr 10, 220-227.
41. Marsen TA, Pollok M, Oette K et al. (1992) Pharmacokinetics of omega-3 fatty acids during ingestion of fish oil preparations. Prostagland Leukotr Essent Fatty Acids 46, 191-196.
42. Blonk MC, Bilo HJ, Popp-Snijders C et al. (1990) Doseresponse effects of fish oil supplementation in healthy volunteers. Am J Clin Nutr 52, 120-127.
43. Katan MB, Deslypere JP, van Birgelen APJM et al. (1997) Kinetics of the incorporation of dietary fatty acids into serum cholesteryl esters, erythrocyte membranes and adipose tissue: an 18 month controlled study. J Lipid Res 38, 2012-2022.
44. Yaqoob P, Pala HS, Cortina-Borja M et al. (2000) Encapsulated fish oil enriched in α-tocopherol alters plasma phospholipid and mononuclear cell fatty acid compositions but not mononuclear cell functions. Eur J Clin Invest 30, 260-274.
45. Rees D, Miles EA, Banerjee T et al. (2006) Dose-related effects of eicosapentaenoic acid on innate immune function in healthy humans: a comparison of young and older men. Am J Clin Nutr 83, 331-342.
46. Faber J, Berkhout M, Vos AP et al. (2011) Supplementation with a fish oil-enriched, high-protein medical food leads to rapid incorporation of EPA into white blood cells and modulates immune responses within one week in healthy men and women. J Nutr 141, 964-970.
47. Popp-Snijders C, Schouten JA, van Blitterswijk WJ et al. (1986) Changes in membrane lipid composition of human erythrocytes after dietary supplementation of (n-3) fatty acids: maintenance of membrane fluidity. Biochim Biophys Acta 854, 31-37.
48. Sanders TAB & Roshanai F (1983) The influence of different types of ω3 polyunsaturated fatty acids on blood lipids and platelet function in healthy volunteers. Clin Sci 64, 91-99.
49. Sperling RI, Benincaso AI, Knoell CT et al. (1993) Dietary ω-3 polyunsaturated fatty acids inhibit phosphoinositide formation, and chemotaxis in neutrophils. J Clin Invest 91, 651-660.
50. Sorensen LS, Rasmussen HH, Aardestrup IV et al. (2014) Rapid incorporation of ω-3 fatty acids into colonic tissue after oral supplementation in patients with colorectal cancer: a randomized, placebo-controlled intervention trial. J Parent Ent Nutr 38, 617-624.
51. Calder PC (2012) Mechanisms of action of (n-3) fatty acids. J Nutr 142, 592S-599S.
52. Calder PC (2013) Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology? Brit J Clin Pharmacol 75, 645-662.
53. Calder PC (2013) n-3 Fatty acids, inflammation and immunity: new mechanisms to explain old actions. Proc Nutr Soc 72, 326-336.
54. Calder PC, Yaqoob P, Harvey DJ et al. (1994) The incorporation of fatty acids by lymphocytes and the effect on fatty acid composition and membrane fluidity. Biochem J 300, 509-518.
55. Miles EA & Calder PC (1998) Modulation of immune function by dietary fatty acids. Proc Nutr Soc 57, 277-292.
56. Niu SL, Mitchell DC, Lim SY et al. (2004) Reduced G protein-coupled signaling efficiency in retinal rod outer segments in response to n-3 fatty acid deficiency. J Biol Chem 279, 31098-31104.
57. Pike LJ (2003) Lipid rafts: bringing order to chaos. J Lipid Res 44, 655-667.
58. Simons K & Gerl MJ (2010) Revitalizing membrane rafts: new tools and insights. Nat Rev Mol Cell Biol 11, 688-699.
59. Yaqoob P (2009) The nutritional significance of lipid rafts. Annu Rev Nutr 29, 257-282.
60. Calder PC & Yaqoob P (2007) Lipid rafts - Composition, characterization and controversies. J Nutr 137, 545-547.
61. Hou TY, McMurray DN & Chapkin RS (2016) Omega-3 fatty acids, lipid rafts, and T cell signaling. Eur J Pharmacol 785, 2-9.
62. Calder PC (2013) Fat chance to enhance B cell function. J Leuk Biol 93, 457-459.
63. Calder PC (2013) Long chain fatty acids and gene expression in inflammation and immunity. Curr Opin Clin Nutr Metab Care 16, 425-433.
64. Novak TE, Babcock TA, Jho DH et al. (2003) NF-kappa B inhibition by omega-3 fatty acids modulates LPS-stimulated macrophage TNF-alpha transcription. Am J Physiol 284, L84-L89.
65. Krey G, Braissant O, L'Horset F et al. (1997) Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol 11, 779-791.
66. Marion-Letellier R, Savoye G & Ghosh S (2016) Fatty acids, eicosanoids and PPAR gamma. Eur J Pharmacol 785, 44-49.
67. Clarke SD (2004) The multi-dimensional regulation of gene expression by fatty acids: polyunsaturated fats as nutrient sensors. Curr Opin Lipidol 15, 13-18.
68. Lapillonne A, Clarke SD & Heird WC (2004) Polyunsaturated fatty acids and gene expression. Curr Opin Clin Nutr Metab Care 7, 151-156.
69. Jump DB (2002) Dietary polyunsaturated fatty acids and regulation of gene transcription. Curr Opin Lipidol 13, 155-1564.
70. Jump DB (2008) N-3 polyunsaturated fatty acid regulation of hepatic gene transcription. Curr Opin Lipidol 19, 242-247.
71. Deckelbaum RJ, Worgall TS & Seo T (2006) N-3 fatty acids and gene expression. Am J Clin Nutr 83, 1520S-1525S.
72. Calder PC (2011) Fatty acids and inflammation: the cutting edge between food and pharma. Eur J Pharmacol 668, S50-S58.
73. Lewis RA, Austen KF & Soberman RJ (1990) Leukotrienes and other products of the 5-lipoxygenase pathway: biochemistry and relation to pathobiology in human diseases. N Engl J Med 323, 645-655.
74. Tilley SL, Coffman TM & Koller BH (2001) Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. J Clin Invest 108, 15-23.
75. Wada M, DeLong CJ, Hong YH et al. (2007) Enzymes and receptors of prostaglandin pathways with arachidonic acidderived versus eicosapentaenoic acid-derived substrates and products. J Biol Chem 282, 22254-22266.
76. Moncada S & Vane JR (1979) The role of prostacyclin in vascular tissue. Fed Proc 38, 68-71.
77. Bannenberg G & Serhan CN (2010) Specialized pro-resolving lipid mediators in the inflammatory response: an update. Biochim Biophys Acta Mol Cell Biol Lipids 1801, 1260-1273.
78. Serhan CN, Chiang N & van Dyke TE (2008) Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 8, 349-361.
79. Serhan CN & Chiang N (2013) Resolution phase lipid mediators of inflammation: agonists of resolution. Curr Opin Pharmacol 13, 632-640.
80. Dalli J, Colas RA & Serhan CN (2013) Novel n-3 immunoresolvents: structures and roles. Sci Rep 3, 1940.
81. Calder PC (2015) Marine omega-3 fatty acids and inflammatory processes: effects, mechanisms and clinical relevance. Biochim Biophys Acta 1851, 469-484.
82. Oh DY, Talukdar S, Bae EJ et al. (2010) GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 142, 687-698.
83. Dyerberg J, Bang HO, Stoffersen E et al. (1978) Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis. Lancet ii, 117-119.
84. Kromann N & Green A (1980) Epidemiological studies in the Upernavik District, Greenland. Acta Med Scand 208, 401-406.
85. Bjerregaard P & Dyerberg J (1988) Mortality from ischemic heart disease and cerebrovascular disease in Greenland. Int J Epidemiol 17, 514-519.
86. Newman WP, Middaugh JP, Propst MT et al. (1993) Atherosclerosis in Alaska Natives and non-natives. Lancet 341, 1056-1057.
87. Bang HO, Dyerberg J & Hjorne N (1976) The composition of foods consumed by Greenland Eskimos. Acta Med Scand 200, 69-73.
88. Yano K, MacLean CJ, Reed DM et al. (1988) A comparison of the 12-year mortality and predictive factors of coronary heart disease among Japanese men in Japan and Hawaii. Am J Epidemiol 127, 476-487.
89. Kris-Etherton PM, Harris WS & Appel LJ (2002) Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. American Heart Association Nutrition Committee. Circulation 106, 2747-2757.
90. von Schacky C (2004) Omega-3 fatty acids and cardiovascular disease. Curr Opin Clin Nutr Metab Care 7, 131-136.
91. London B, Albert C, Anderson M et al. (2007) Omega-3 fatty acids and cardiac arrhythmias: prior studies and recommendations for future research: a report from the National Heart, Lung, and Blood Institute and Office Of Dietary Supplements Omega-3 Fatty Acids and their Role in Cardiac Arrhythmogenesis Workshop. Circulation 116, e320-e335.
92. Wang C, Harris WS, Chung M et al. (2006) n-3 Fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primaryand secondary-prevention studies: a systematic review. Am J Clin Nutr 84, 5-17.
93. Calder PC (2004) n-3 Fatty acids and cardiovascular disease: evidence explained and mechanisms explored. Clin Sci 107, 1-11.
94. Chowdhury R, Warnakula S, Kunutsor S et al. (2014) Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis. Ann Intern Med 160, 398-406.
95. Del Gobbo LC, Imamura F, Aslibekyan S et al. (2016) ω-3 Polyunsaturated fatty acid biomarkers and coronary heart disease: pooling project of 19 cohort studies. JAMA Intern Med 176, 1155-1166.
96. Calder PC (2017) New evidence that omega-3 fatty acids have a role in primary prevention of coronary heart disease. J Pub Health Emerg 1, 35.
97. Harris WS (1996) N-3 fatty acids and lipoproteins: comparison of results from human and animal studies. Lipids 31, 243-252.
98. Saravanan P, Davidson NC, Schmidt EB et al. (2010) Cardiovascular effects of marine omega-3 fatty acids. Lancet 376, 540-550.
99. De Caterina R (2011) n-3 fatty acids in cardiovascular disease. N Engl J Med 364, 2439-2450.
100. Balk EM, Lichtenstein AH, Chung M et al. (2006) Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. Atherosclerosis 189, 19-30.
101. Leslie MA, Cohen DJ, Liddle DM et al. (2015) A review of the effect of omega-3 polyunsaturated fatty acids on blood triacylglycerol levels in normolipidemic and borderline hyperlipidemic individuals. Lipids Health Dis 14, 53.
102. AbuMweis S, Jew S, Tayyem R et al. (2017) Eicosapentaenoic acid and docosahexaenoic acid containing supplements modulate risk factors for cardiovascular disease: a meta-analysis of randomised placebo-control human clinical trials. J Hum Nutr Diet (In the Press).
103. Mori TA, Burke V, Puddey IB et al. (2000) Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Am J Clin Nutr 71, 1085-1094.
104. Burr ML, Fehily AM, Gilbert JF et al. (1989) Effects of changes in fat, fish and fibre intake on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet ii, 757-761.
105. Anonymous (1999) Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 354, 447-455.
106. Marchioli R, Barzi F, Bomba E et al. (2002) Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction - Time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 105, 1897-1903.
107. Yokoyama M, Origasa H, Matsuzaki M et al. (2007) Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 369, 1090-1098.
108. Gissi-HF Investigators, Tavazzi L, Maggioni AP, Marchioli R et al. (2008). Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebocontrolled trial. Lancet 372, 1223-1230.
109. Bucher HC, Hengstler P, Schindler C et al. (2002) N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med 112, 298-304.
110. Studer M, Briel M, Leimenstoll B et al. (2005) Effect of different antilipidemic agents and diets on mortality: a systematic review. Arch Intern Med 165, 725-730.
111. Leon H, Shibata MC, Sivakumaran S et al. (2009) Effect of fish oil on arrhythmias and mortality: systematic review. Brit Med J 338, a2931.
112. Harris WS, Miller M, Tighe AP et al. (2008) Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis 197, 12-24.
113. Xin W, Wei W & Li XY (2013) Short-term effects of fishoil supplementation on heart rate variability in humans: a meta-analysis of randomized controlled trials. Am J Clin Nutr 97, 926-935.
114. Leaf A & Xiao YF (2001) The modulation of ionic currents in excitable tissues by n-3 polyunsaturated fatty acids. J Memb Biol 184, 263-271.
115. Thies F, Garry JMC, Yaqoob P et al. (2003) Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. Lancet 361, 477-485.
116. Cawood AL, Ding R, Napper FL et al. (2010) Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability. Atherosclerosis 212, 252-259.
117. Calder PC & Yaqoob P (2010) Omega-3 (n-3) fatty acids, cardiovascular disease and stability of atherosclerotic plaques. Cell Mol Biol 56, 28-37.
118. Galan P, Kesse-Guyot E, Czernichow S et al. (2010) Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ 341, c6273.
119. Kromhout D, Giltay EJ, Geleijnse JM et al. (2010) n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med 363, 2015-2026.
120. Rauch B, Schiele R, Schneider S et al. (2010) OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation 122, 2152-2159.
121. Risk and Prevention Study Collaborative Group, Roncaglioni MC, Tombesi M, Avanzini F et al. (2013) n-3 fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med 368, 1800-1808.
122. Bosch J, Gerstein HC, Dagenais GR et al. (2012) n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med 367, 309-318.
123. Kwak SM, Myung SK, Lee YJ et al. (2012) Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials. Arch Intern Med 172, 686-694.
124. Kotwal S, Jun M, Sullivan D et al. (2012) Omega 3 Fatty acids and cardiovascular outcomes: systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes 5, 808-818.
125. Rizos EC, Ntzani EE, Bika E et al. (2012) Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. J Am Med Assoc 308, 1024-1033.
126. Calder PC & Yaqoob P (2012) Marine omega-3 fatty acids and coronary heart disease. Curr Opin Cardiol 27, 412-419.
127. Casula M, Soranna D, Catapano AL et al. (2013) Longterm effect of high dose omega-3 fatty acidsupplementation for secondary prevention of cardiovascular outcomes: a meta-analysis of randomized, double blind, placebo controlled trials. Atheroscler Suppl 14, 243-251.
128. Wen YT, Dai JH & Gao Q (2014) Effects of omega-3 fatty acid on major cardiovascular events and mortality in patients with coronary heart disease: a meta-analysis of randomized controlled trials. Nutr Metab Cardiovasc Dis 24, 470-475.
129. Siscovick DS, Barringer TA, Fretts AM et al. (2017) Omega-3 polyunsaturated fatty acid (fish oil) supplementation and the prevention of clinical cardiovascular disease: a science advisory from the American Heart Association. Circulation 135, e867-e884.
130. Gleissman H, Johnsen JI & Kogner P (2010) Omega-3 fatty acids in cancer, the protectors of good and the killers of evil? Exp Cell Res 316, 1365-1373.
131. Merendino N, Costantini L, Manzi L et al. (2013) Dietary ω-3 polyunsaturated fatty acids DHA: a potential adjuvant in the treatment of cancer. BioMed Res Int 2013; 310186.
132. Wang D & Dubois RN (2010) Eicosanoids and cancer. Nat Rev Cancer 10, 181-193.
133. Vaughan VC, Hassing MR & Lewandowski PA (2013) Marine polyunsaturated fatty acids and cancer therapy. Brit J Cancer 108, 486-492.
134. Murphy RA, Mourtzakis M & Mazurak VC (2012) n-3 polyunsaturated fatty acids: the potential role for supplementation in cancer. Curr Opin Clin Nutr Metab Care 15, 246-251.
135. Yang B, Wang FL, Ren XL et al. (2014) Biospecimen long-chain n-3 PUFA and risk of colorectal cancer: a meta-analysis of data from 60,627 individuals. PLoS ONE 9, e110574.
136. Makarem N, Chandran U, Bandera EV et al. (2013) Dietary fat in breast cancer survival. Annu Rev Nutr 33, 319-348.
137. Sczaniecka AK, Brasky TM, Lampe JW et al. (2012) Dietary intake of specific fatty acids and breast cancer risk among postmenopausal women in the VITAL cohort. Nutr Cancer 64, 1131-1142.
138. Brasky TM, Darke AK, Song X et al. (2013) Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. J Natl Cancer Inst 105, 1132-1141.
139. Crowe FL, Appleby PN, Travis RC et al. (2014) Circulating fatty acids and prostate cancer risk: individual participant meta-analysis of prospective studies. J Natl Cancer Inst 106, dju240.
140. Elia M, Van Bokhorst-de van der Schueren MA, Garvey J et al. (2006) Enteral (oral or tube administration) nutritional support and eicosapentaenoic acid in patients with cancer: a systematic review. Int J Oncol 28, 5-23.
141. Alfano CM, Imayama I, Neuhouser ML et al. (2012) Fatigue, inflammation, and ω-3 and ω-6 fatty acid intake among breast cancer survivors. J Clin Oncol 30, 1280-1287.
142. Cerchietti LC, Navigante AH & Castro MA (2007) Effects of eicosapentaenoic and docosahexaenoic n-3 fatty acids from fish oil and preferential Cox-2 inhibition on systemic syndromes in patients with advanced lung cancer. Nutr Cancer 59, 14-20.
143. van der Meij BS, Langius JA, Spreeuwenberg MD et al. (2012) Oral nutritional supplements containing n-3 polyunsaturated fatty acids affect quality of life and functional status in lung cancer patients during multimodality treatment: an RCT. Eur J Clin Nutr 66, 399-404.
144. Sala-Vila A, Folkes J & Calder PC (2010) The effect of three lipid emulsions differing in fatty acid composition on growth, apoptosis and cell cycle arrest in the HT-29 colorectal cancer cell line. Clin Nutr 29, 519-524.
145. Murphy RA, Mourtzakis M, Chu QS et al. (2011) Supplementation with fish oil increases first-line chemotherapy efficacy in patients with advanced nonsmall cell lung cancer. Cancer 117, 3774-3780.
146. Bougnoux P, Hajjaji N, Ferrasson MN et al. (2009) Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial. Brit J Cancer 101, 1978-1985.
147. Weed HG, Ferguson ML, Gaff RL et al. (2011) Lean body mass gain in patients with head and neck squamous cell cancer treated perioperatively with a protein- and energy-dense nutritional supplement containing eicosapentaenoic acid. Head Neck 33, 1027-1033.
148. Murphy RA, Mourtzakis M, Chu QS et al. (2011) Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving chemotherapy. Cancer 117, 1775-1782.
149. Fearon KC, Barber MD, Moses AG et al. (2006) Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. J Clin Oncol 24, 3401-3407.
150. Guarcello M, Riso S, Buosi R et al. (2007) EPA-enriched oral nutritional support in patients with lung cancer: effects on nutritional status and quality of life. Nutr Therap Metab 25, 25-30.
151. Calder PC, Albers R, Antoine JM et al. (2009) Inflammatory disease processes and interactions with nutrition. Brit J Nutr 101, Suppl. 1, S1-45.
152. Calder PC, Ahluwalia N, Albers R et al. (2013) A consideration of biomarkers to be used for evaluation of inflammation in human nutritional studies. Brit J Nutr 109, Suppl. 1, S1-S34.
153. Ross R (1999) Atherosclerosis-an inflammatory disease. N Engl J Med 340, 115-126.
154. Hansson GK & Hermansson A (2011) The immune system in atherosclerosis. Nat Immunol 12, 204-212.
155. Calder PC, Ahluwalia N, Brouns F et al. (2011) Dietary factors and low-grade inflammation in relation to overweight and obesity. Brit J Nutr 106, Suppl. 3, S5-S78.
156. Colotta F, Allavena P, Sica A et al. (2009) Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30, 1073-1081.
157. Miles EA & Calder PC (2012) Influence of marine n-3 polyunsaturated fatty acids on immune function and a systematic review of their effects on clinical outcomes in rheumatoid arthritis. Brit J Nutr 107, Suppl. 2, S171-S184.
158. Calder PC (2009) Fatty acids and immune function: relevance to inflammatory bowel diseases. Int Rev Immunol 28, 506-534.
159. Calder PC (2006) n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 83, 1505S-1519S.
160. Abdulrazaq M, Innes JK & Calder PC (2017) Effect of ω-3 polyunsaturated fatty acids on arthritic pain: a systematic review. Nutrition 39-40, 57-66.
161. Senftleber NK, Nielsen SM, Andersen JR et al. (2017) Marine oil supplements for arthritis pain: a systematic review and meta-analysis of randomized trials. Nutrients 9, 42.
162. Calder PC, Kremmyda LS, Vlachava M et al. (2010) Is there a role for fatty acids in early life programming of the immune system? Proc Nutr Soc 69, 373-380.
163. Dunstan JA, Mori TA, Barden A et al. (2003) Maternal fish oil supplementation in pregnancy reduces interleukin-13 levels in cord blood of infants at high risk of atopy. Clin Exp Allergy 33, 442-448.
164. Dunstan JA, Mori TA, Barden A et al. (2003) Fish oil supplementation in pregnancy modifies neonatal allergen-specific immune responses and clinical outcomes in infants at high risk of atopy: a randomized, controlled trial. J Allergy Clin Immunol 112, 1178-1184.
165. Noakes PS, Vlachava M, Kremmyda LS et al. (2012) Increased intake of oily fish in pregnancy: effects on neonatal immune responses and on clinical outcomes in infants at 6 mo. Am J Clin Nutr 95, 395-404.
166. Furuhjelm C, Warstedt K, Larsson J et al. (2009) Fish oil supplementation in pregnancy and lactation may decrease the risk of infant allergy. Acta Paediatr 98, 1461-1467.
167. Palmer DJ, Sullivan T, Gold MS et al. (2012) Effect of n-3 long chain polyunsaturated fatty acid supplementation in pregnancy on infants' allergies in first year of life: randomised controlled trial. Brit Med J 344, e184.
168. Best KP, Gold M, Kennedy D et al. (2016) Omega-3 longchain PUFA intake during pregnancy and allergic disease outcomes in the offspring: asystematic review and meta-analysis of observational studies and randomized controlled trials. Am J Clin Nutr 103, 128-143.
169. Bisgaard H, Stokholm J, Chawes BL et al. (2016) Fish oilderived fatty acids in pregnancy and wheeze and asthma in offspring. N Engl J Med 375, 2530-2539.
170. D'Vaz N, Meldrum SJ, Dunstan JA et al. (2012) Fish oil supplementation in early infancy modulates developing infant immune responses. Clin Exp Allergy 42, 1206-1216.
171. Willemsen LEM (2016) Dietary n-3 long chain polyunsaturated fatty acids in allergy prevention and asthma treatment. Eur J Pharmacol 785, 174-186.
172. Klemens CM, Berman DR & Mozurkewich EL (2011) The effect of perinatal omega-3 fatty acid supplementation on inflammatory markers and allergic disease: a systematic review. Brit J Obstet Gynaecol 118, 916-925.
173. Miles EA & Calder PC (2017) Can early omega-3 fatty acid exposure reduce risk of childhood allergic disease? Nutrients 9, 784.
174. Lauritzen L, Hansen HS, Jorgensen MH et al. (2001) The essentiality of long chain n-3 fatty acids in relation to development and function of the brain and retina. Prog Lipid Res 40, 1-94.
175. Salem N, Litman B, Kim HY et al. (2001) Mechanisms of action of docosahexaenoic acid in the nervous system. Lipids 36, 945-959.
176. Parletta N, Milte CM & Meyer BJ (2013) Nutritional modulation of cognitive function and mental health. J Nutr Biochem 24, 725-743.
177. Uauy RD, Birch DG, Birch EE et al. (1990) Effect of dietary omega-3 fatty acids on retinal function of very-lowbirth-weight neonates. Pediatr Res 28, 485-492.
178. Birch DG, Birch EE, Hoffman DR et al. (1992) Retinal development in very-low-birth-weight infants fed diets differing in omega-3 fatty acids. Invest Opthalmol Vis Sci 33, 2365-2376.
179. Birch EE, Birch DG, Hoffman DR et al. (1992) Dietary essential fatty acid supply and visual acuity development. Invest Opthalmol Vis Sci 33, 3242-3253.
180. Carlson SE, Werkman SH, Rhodes PG et al. (1993) Visual acuity development in healthy preterm infants: effect of marine oil supplementation. Am J Clin Nutr 58, 35-42.
181. Carlson SE, Ford AJ, Werkman SH et al. (1996) Visual acuity and fatty acid status of term infants fed human milk and formulas with and without docosahexaenoate and arachidonate from egg yolk lecithin. Pediatr Res 39, 882-888.
182. Carlson SE, Werkman SH & Tolley EA (0000) Effect of long-chain n-3 fatty acid supplementation on visual acuity and growth of preterm infants with and without bronchopulmonary dysplasia. Am J Clin Nutr 63, 687-697.
183. Moon K, Rao SC, Schulzke SM et al. (2016) Long-chain polyunsaturated fatty acid supplementation in preterm infants. Cochrane Database Syst Rev 12, CD000375.
184. Molloy C, Doyle LW, Makrides M et al. (2012) Docosahexaenoic acid and visual functioning in preterm infants: a review. Neuropsychol Rev 22, 425-437.
185. Agostoni C, Trojan S, Bellu R et al. (1995) Neurodevelopmental quotient of healthy term infants at 4 months and feeding practice: the role of long-chain polyunsaturated fatty acids. Pediatr Res 38, 262-266.
186. Willatts P, Forsyth JS, DiModugno MK et al. (1998) Effect of long-chain polyunsaturated fatty acids in infant formula on problem solving at 10 months of age. Lancet 352, 688-691.
187. Scott DT, Janowsky JS, Carroll RE et al. (1998) Formula supplementation with long-chain polyunsaturatedfatty acids: are there developmental benefits? Pediatrics 102, E59.
188. Makrides M, Neumann MA, Simmer K et al. (2000) A critical appraisal of the role of dietary long-chain polyunsaturated fatty acids on neural indices of term infants: a randomized, controlled trial. Pediatrics 105, 32-38.
189. Auested N, Halter R, Hall RT et al. (2001) Growth and development of term infants fed long-chain polyunsaturated fatty acids: a double-masked, randomized, parallel, prospective, multivariate study. Pediatrics 108, 272-381.
190. Auested N, Scott DT, Janowsky JS et al. (2003) Visual, cognitive, and language assessments at 39 months: a follow-up study of children fed formulas containing longchain polyunsaturated fatty acids to 1 year of age. Pediatrics 112, e177-e183.
191. Agostoni C, Trojan S, Bellu R et al. (1997) Developmental quotient at 24 months and fatty acid composition of diet in early infancy: a follow up study. Arch Dis Child 1997, 76, 421-424.
192. Jasani B, Simmer K, Patole SK et al. (2017) Long chain polyunsaturated fatty acid supplementation in infants born at term. Cochrane Database Syst Rev 3, CD000376.
193. Gould JF, Smithers LG & Makrides M (2013) The effect of maternal omega-3 (n-3) LCPUFA supplementation during pregnancy on early childhood cognitive and visual development; a systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr 97, 531-544.
194. Richardson AJ (2004) Clinical trials of fatty acid treatment in ADHD, dyslexia, dyspraxia and the autistic spectrum. Prostagland Leuk Essent Fatty Acids 70, 383-390.
195. Stevens L, Zhang W, Peck L et al. (2003) EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors. Lipids 38, 1007-1021.
196. Richardson AJ & Puri BK (2002) A randomized doubleblind, placebo-controlled study of the effects of supplementation with highly unsaturated fatty acids on ADHD-related symptoms in children with specific learning difficulties. Prog Neuropsychopharmacol Biol Psych 26, 233-239.
197. Yui K, Koshiba M, Nakamura S et al. (2012) Effects of large doses of arachidonic acid added to docosahexaenoic acid on social impairment in individuals with autism spectrum disorders: a double-blind, placebo-controlled, randomized trial. J Clin Psychopharmacol 32, 200-206.
198. Meguid NA, Atta HM, Gouda AS et al. (2008) Role of polyunsaturated fatty acids in the management of Egyptian children with autism. Clin Biochem 41, 1044-1048.
199. Perera H, Jeewandara KC, Seneviratne S et al. (2012) Combined ω3 and ω6 supplementation in children with attention-deficit hyperactivity disorder (ADHD) refractory to methylphenidate treatment: a double-blind, placebo-controlled study. J Child Neurol 27, 747-753.
200. Milte CM, Parletta N, Buckley JD et al. (2012) Eicosapentaenoic and docosahexaenoic acids, cognition, and behavior in children with attention-deficit/hyperactivity disorder: a randomized controlled trial. Nutrition 28, 670-677.
201. Gustafsson PA, Birberg-Thornberg U, Duchén K et al. (2010) EPA supplementation improves teacher-rated behaviour and oppositional symptoms in children with ADHD. Acta Paediatr 99, 1540-1549.
202. Bélanger SA, Vanasse M, Spahis S et al. (2009) Omega-3 fatty acid treatment of children with attention-deficit hyperactivity disorder: a randomized, double-blind, placebo-controlled study. Paediatr Child Health 14, 89-98.
203. Sorgi PJ, Hallowell EM, Hutchins HL et al. (2007) Effects of an open-label pilot study with high-dose EPA/DHA concentrates on plasma phospholipids and behavior in children with attention deficit hyperactivity disorder. Nutr J 6, 16.
204. Bos DJ, Oranje B, Veerhoek ES et al. (2015) Reduced symptoms of inattention after dietary omega-3 fatty acid supplementation in boys with and without attention deficit/hyperactivity disorder. Neuropsychopharmacol 40, 2298-2306.
205. Sheppard KW, Boone KM, Gracious B et al. (2017) Effect of omega-3 and -6 supplementation on language in preterm toddlers exhibiting autism spectrum disorder symptoms. J Autism Dev Disord (In the Press).
206. Voigt RG, Llorente AM, Jensen CL et al. (2001) A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder. J Pediatr 139, 189-196.
207. Hirayama S, Hamazaki T & Terasawa K (2004) Effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder - a placebo-controlled double-blind study. Eur J Clin Nutr 58, 467-473.
208. Bent S, Bertoglio K, Ashwood P et al. (2011) A pilot randomized controlled trial of omega-3 fatty acids for autism spectrum disorder. J Autism Dev Disord 41, 545-554.
209. Politi P, Cena H, Comelli M et al. (2008) Behavioral effects of omega-3 fatty acid supplementation in young adults with severe autism: an open label study. Arch Med Res 39, 682-685.
210. Amminger GP, Berger GE, Schäfer MR et al. (2007) Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot study. Biol Psychiatry 61, 551-553.
211. Johnson M, Ostlund S, Fransson G et al. (2009) Omega-3/omega-6 fatty acids for attention deficit hyperactivity disorder: a randomized placebo-controlled trial in children and adolescents. J Atten Disord 12, 394-401.
212. Raz R, Carasso RL & Yehuda S (2009) The influence of short-chain essential fatty acids on children with attention-deficit/hyperactivity disorder: a double-blind placebo-controlled study. J Child Adolesc Psychopharmacol 19, 167-177.
213. Voigt RG, Mellon MW, Katusic SK et al. (2014) Dietary docosahexaenoic acid supplementation in children with autism. J Pediatr Gastroenterol Nutr 58, 715-722.
214. Mankad D, Dupuis A, Smile S et al. (2015) A randomized, placebo controlled trial of omega-3 fatty acids in the treatment of young children with autism. Mol Autism 6, 18.
215. Frensham LJ, Bryan J & Parletta N (2012) Influences of micronutrient and omega-3 fatty acid supplementation on cognition, learning, and behaviour: methodological considerations and implications for children and adolescents in developed societies. Nutr Rev 70, 594-610.
216. Horvath A, Łukasik J & Szajewska H (2017) ω-3 Fatty acid supplementation does not affect autism spectrum disorder in children: a systematic review and meta-analysis. J Nutr 147, 367-376.
217. Mazahery H, Stonehouse W, Delshad M et al. (2017) Relationship between long chain n-3 polyunsaturated fatty acids and autism spectrum disorder: systematic review and meta-analysis of case-control and randomised controlled trials. Nutrients 9, 155.
218. Cooper RE, Tye C, Kuntsi J et al. (2016) The effect of omega-3 polyunsaturated fatty acid supplementation on emotional dysregulation, oppositional behaviour and conduct problems in ADHD: a systematic review and meta-analysis. J Affect Disord 190, 474-482.
219. Chang JC, Su KP, Mondelli V et al. (2017) Omega-3 polyunsaturated fatty acids in youths with attention deficit hyperactivity disorder (ADHD): A systematic review and meta-analysis of clinical trials and biological studies. Neuropsychopharmacol (In the Press).
220. Derbyshire E (2017) Do omega-3/6 fatty acids have a therapeutic role in children and young people with ADHD? J Lipids (In the Press).
221. Rudin DO (1981) The major psychoses and neuroses as omega-3 essential fatty acid deficiency syndrome: substrate pellagra. Biol Psychiatry 16, 837-850.
222. Hibbeln JR (1998) Fish consumption and major depression. Lancet 351, 1213.
223. Su KP, Huang SY, Chiu CC et al. (2003) Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. Eur Neuropsychopharmacol 13, 267-271.
224. Marangell LB, Martinez JM, Zboyan HA et al. (2003) A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression. Am J Psychiatry 160, 996-998.
225. Stoll AL, Severus WE, Freeman MP et al. (1999) Omega 3 fatty acids in bipolar disorder: a preliminary doubleblind, placebo-controlled trial. Arch Gen Psychiatry 56, 407-412.
226. Nemets B, Stahl Z & Belmaker RH (2002) Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry 159, 477-479.
227. Mocking RJ, Harmsen I, Assies J et al. (2016) Meta-analysis and meta-regression of omega-3 polyunsaturated fatty acid supplementation for major depressive disorder. Transl Psychiatry 6, e756.
228. Sublette ME, Ellis SP, Geant AL et al. (2012) Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression. J Clin Psychiatry 72, 1577-1584.
229. Sarris J, Mischoulon D & Schweitzer I (2012) Omega-3 for bipolar disorder: meta-analyses of use in mania and bipolar depression. J Clin Psychiatry 73, 81-86.
230. Appleton KM, Sallis HM, Perry R et al. (2016) ω-3 Fatty acids for major depressive disorder in adults: an abridged Cochrane review. BMJ Open 6, e010172.
231. Peet M, Laugharne J, Rangarajan N et al. (1995) Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients. J Psychiatr Res 29, 227-232.
232. Yao JK, van Kammen DP & Welker JA (1994) Red blood cell membrane dynamics in schizophrenia. II. Fatty acid composition. Schizophr Res 13, 217-226.
233. Glen AI, Glen EM, Horrobin DF et al. (1994) A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases. Schizophr Res 12, 53-61.
234. Edwards R, Peet M, Shay J et al. (1998) Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients. J Affect Disord 48, 149-155.
235. Hoen WP, Lijmer JG, Duran M et al. (2013) Red blood cell polyunsaturated fatty acids measured in red blood cells and schizophrenia: a meta-analysis. Psychiatry Res 207, 1-12.
236. Peet M, Brind J, Ramchand CN et al. (2001) Two doubleblind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr Res 49, 243-251.
237. Peet M & Horrobin DF (2002) A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry 59, 913-919.
238. Fenton WS, Dickerson F, Boronow J et al. (2001) A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am J Psychiatry 158, 2071-2074.
239. Emsley R, Myburgh C, Oosthuizen P et al. (2002) Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am J Psychiatry 159, 1596-1598.
240. Pawełczyk T, Grancow-Grabka M, Kotlicka-Antczak M et al. (2016) A randomized controlled study of the efficacy of six-month supplementation with concentrated fish oil rich in omega-3 polyunsaturated fatty acids in first episode schizophrenia. J Psychiatr Res 73, 34-44.
241. Joy CB, Mumby-Croft R & Joy LA (2006) Polyunsaturated fatty acid supplementation for schizophrenia. Cochrane Database Syst Rev 3, CD001257.
242. Zanarini MC & Frankenburg FR (2003) N-3 fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study. Am J Psychiatry 160, 167-169.
243. Hamazaki T, Sawazaki S, Itomura M et al. (1996) The effect of docosahexaenoic acid on aggression in young adults. A placebo-controlled double-blind study. J Clin Invest 97, 1129-1133.
244. Hamazaki T, Thienprasert A, Kheovichai K et al. (2002) The effect of docosahexaenoic acid on aggression in elderly Thai subjects-a placebo-controlled double-blind study. Nutr Neurosci 5, 37-41.
245. Prasad MR, Lovell MA, Yatin M et al. (1998) Regional membrane phospholipid alterations in Alzheimer's disease. Neurochem Res 23, 81-88.
246. Tully AM, Roche HM, Doyle R et al. (2003) Low serum cholesteryl ester-docosahexaenoic acid levels in Alzheimer's disease: a case-control study. Brit J Nutr 89, 483-489.
247. Cunnane SC, Schneider JA, Tangney C et al. (2012) Plasma and brain fatty acid profile in mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis 29, 691-697.
248. Soderberg M, Edlund C, Kristensson K et al. (1991) Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease. Lipids 26, 421-425.
249. Conquer JA, Tierney MC, Zecevic J et al. (2000) Fatty acid analysis of blood plasma of patients with Alzheimer's disease, other types of dementia, and cognitive impairment. Lipids 35, 1305-1312.
250. Sinn N, Milte CM, Street SJ et al. (2012) Effects of n-3 fatty acids, EPA v. DHA, on depressive symptoms, quality of life, memory and executive function in older adults with mild cognitive impairment: a 6-month randomised controlled trial. Brit J Nutr 107, 1682-1693.
251. Scheltens P, Twisk JW, Blesa R et al. (2012) Efficacy of Souvenaid in mild Alzheimer's disease: results from a randomized, controlled trial. J Alzheimers Dis 31, 225-236.
252. Quinn JF, Raman R, Thomas RG et al. (2010) Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. J Am Med Assoc 304, 1903-1911.
253. Freund-Levi Y, Eriksdotter-Jönhagen M, Cederholm T et al. (2006) Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol 63, 1402-1408.
254. Freund-Levi Y, Basun H, Cederholm T et al. (2008) Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. Int J Geriatr Psychiatry 23, 161-169.
255. Kotani S, Sakaguchi E, Warashina S et al. (2006) Dietary supplementation of arachidonic and docosahexaenoic acids improves cognitive dysfunction. Neurosci Res 56, 159-164.
256. Boston PF, Bennett A, Horrobin DF et al. (2204) Ethyl-EPA in Alzheimer's disease - a pilot study. Prostagland Leukot Essent Fatty Acids 71, 341-346.
257. Phillips MA, Childs CE, Calder PC et al. (2015) No effect of omega-3 fatty acid supplementation on cognition and mood in individuals with cognitive impairment and probable Alzheimer's disease: a randomised controlled trial. Int J Mol Sci 16, 24600-24613.
258. Sydenham E, Dangour AD & Lim WS (2012) Omega 3 fatty acid for the prevention of cognitive decline and dementia. Cochrane Database Syst Rev 6, CD005379.
259. Zhang XW, Hou WS, Li M et al. (2016) Omega-3 fatty acids and risk of cognitive decline in the elderly: a metaanalysis of randomized controlled trials. Aging Clin Exp Res 28, 165-166.
260. Burckhardt M, Herke M, Wustmann T et al. (2016) Omega-3 fatty acids for the treatment of dementia. Cochrane Database Syst Rev 4, CD009002.
261. Andrieu S, Guyonnet S, Coley N et al. (2017) Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. Lancet Neurol 16, 377-389.
262. Simopolous AP, Leaf A & Salem N (1999) Essentiality and recommended dietary intakes for omega-6 and omega-3 fatty acids. Ann Nutr Metab 43, 127-130.
263. International Society for the Study of Fatty Acids and Lipids (2004) Recommendations for the intake of polyunsaturated fatty acids in healthy adults (ISSFAL Policy Statement 3). http://www.issfal.org/news-links/resources/publications/PUFAIntakeReccomdFinalReport.pdf.
264. French Agency for Food, Environmental and Occupational Health Safety (2003) The omega-3 fatty acids and the cardiovascular system: nutritional benefits and claims. http://www.afssa.fr?Documents?NUT-Raomega3EN.pdf.
265. National Health and Medical Research Council (2006) Nutrient reference values for Australia and New Zealand including recommended dietary intakes. http://www.nhmrc.gov.au/publications/synopses/n35syn.htm.
266. Food and Agricultural Organisation of the United Nations (2010) Fat and Fatty Acids in Human Nutrition: report of an Expert Consultation. Food and Agricultural Organisation of the United Nations, Rome.
267. European Food Safety Authority (2010) Scientific opinion on dietary reference values for fats, including saturated fatty acids, polyunsaturated fatty acids, monounsaturated fatty acids, trans fatty acids and cholesterol. EFSA J 8, 1461.
268. Mori TA & Woodman RJ (2006) The independent effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular risk factors in humans. Curr Opin Clin Nutr Metab Care 9, 95-104.
269. Wei MY & Jacobson TA (2011) Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis. Curr Atheroscler Rep 13, 474-483.
270. Schuchardt JP & Hahn A (2013) Bioavailability of longchain omega-3 fatty acids. Prostaglandins Leukot Essent Fatty Acids 89, 1-8.
271. Ghasemifard S, Turchini GM & Sinclair AJ (2014) Omega-3 long chain fatty acid 'bioavailability': a review of evidence and methodological considerations. Prog Lipid Res 56, 92-108.
272. Raatz SK, Johnson LK & Bukowski MR (2016) Enhanced bioavailability of EPA from emulsified fish oil preparations versus capsular triacylglycerol. Lipids 51, 643-651.
273. Ruiz-Lopez N, Usher S, Sayanova OV et al. (2015) Modifying the lipid content and composition of plant seeds: engineering the production of LC-PUFA. Appl Microbiol Biotechnol 99, 143-154.
274. Walker CG, Jebb SA & Calder PC (2013) Stearidonic acid as a supplemental source of ω-3 polyunsaturated fatty acids to enhance status for improved human health. Nutrition 29, 363-369.
275. James MJ, Ursin VM & Cleland LG (2003) Metabolism of stearidonic acid in human subjects: comparison with the metabolism of other n-3 fatty acids. Am J Clin Nutr 77, 1140-1145.